Article Details

CD38/48 Upregulation With Tazemetostat May Overcome Daratumumab Resistance in ... - OncLive

Retrieved on: 2023-09-29 23:38:39

Tags for this article:

Click the tags to see associated articles and topics

CD38/48 Upregulation With Tazemetostat May Overcome Daratumumab Resistance in ... - OncLive. View article details on hiswai:

Excerpt

Daratumumab was the first FDA-approved anti-CD38 monoclonal antibody in multiple myeloma and has received multiple FDA approvals since for both ...

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up